The US Food and Drug Administration is seeking input on whether to launch a pilot program to evaluate the safety of novel excipients through an independent review process.
Industry proponents argue that such a process would spur development of
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?